Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
NRAS Q61K
i
Other names:
NRAS1, HRAS1, N-Ras Protein Part 4, Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog, NRAS, Neuroblastoma RAS Viral Oncogene Homolog, NRAS Proto-Oncogene, GTPase
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4893
Related biomarkers:
Expression
Mutation
CNA
Others
‹
EGFR exon 19 deletion + NRAS Q61K (3)
PD-L1 expression + NRAS Q61R + BRAF D594N (2)
CDKN2A Negative + NRAS Mutation (1)
Chr t(11;14) + NRAS mutation (1)
KRAS wild-type + NRAS wild-type + MSI-H/dMMR (1)
MLL-AFF1 fusion + NRAS mutation (1)
NRAS mutation + BRAF wild-type (1)
NRAS wild-type + NOTCH4 mutation (1)
EGFR exon 19 deletion + NRAS Q61K (3)
PD-L1 expression + NRAS Q61R + BRAF D594N (2)
CDKN2A Negative + NRAS Mutation (1)
Chr t(11;14) + NRAS mutation (1)
KRAS wild-type + NRAS wild-type + MSI-H/dMMR (1)
MLL-AFF1 fusion + NRAS mutation (1)
NRAS mutation + BRAF wild-type (1)
NRAS wild-type + NOTCH4 mutation (1)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
NRAS Q61K
Melanoma
NRAS Q61K
Melanoma
trametinib + dabrafenib
Resistant: C3 – Early Trials
trametinib + dabrafenib
Resistant
:
C3
trametinib + dabrafenib
Resistant: C3 – Early Trials
trametinib + dabrafenib
Resistant
:
C3
NRAS Q61K
Hepatocellular Cancer
NRAS Q61K
Hepatocellular Cancer
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
sorafenib + BAY86-9766
Sensitive
:
C3
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
sorafenib + BAY86-9766
Sensitive
:
C3
NRAS Q61K
Melanoma
NRAS Q61K
Melanoma
vemurafenib
Resistant: C3 – Early Trials
vemurafenib
Resistant
:
C3
vemurafenib
Resistant: C3 – Early Trials
vemurafenib
Resistant
:
C3
NRAS Q61K
Melanoma
NRAS Q61K
Melanoma
tunlametinib
Sensitive: C3 – Early Trials
tunlametinib
Sensitive
:
C3
tunlametinib
Sensitive: C3 – Early Trials
tunlametinib
Sensitive
:
C3
NRAS Q61K
Thyroid Gland Carcinoma
NRAS Q61K
Thyroid Gland Carcinoma
selumetinib
Sensitive: C3 – Early Trials
selumetinib
Sensitive
:
C3
selumetinib
Sensitive: C3 – Early Trials
selumetinib
Sensitive
:
C3
NRAS Q61K
Non Small Cell Lung Cancer
NRAS Q61K
Non Small Cell Lung Cancer
trametinib
Sensitive: C3 – Early Trials
trametinib
Sensitive
:
C3
trametinib
Sensitive: C3 – Early Trials
trametinib
Sensitive
:
C3
NRAS Q61K
Multiple Myeloma
NRAS Q61K
Multiple Myeloma
Resistant: C3 – Early Trials
Resistant
:
C3
Resistant: C3 – Early Trials
Resistant
:
C3
NRAS Q61K
Melanoma
NRAS Q61K
Melanoma
LY3009120
Sensitive: D – Preclinical
LY3009120
Sensitive
:
D
LY3009120
Sensitive: D – Preclinical
LY3009120
Sensitive
:
D
NRAS Q61K
Melanoma
NRAS Q61K
Melanoma
trametinib + palbociclib
Resistant: D – Preclinical
trametinib + palbociclib
Resistant
:
D
trametinib + palbociclib
Resistant: D – Preclinical
trametinib + palbociclib
Resistant
:
D
NRAS Q61K
Melanoma
NRAS Q61K
Melanoma
selumetinib
Sensitive: D – Preclinical
selumetinib
Sensitive
:
D
selumetinib
Sensitive: D – Preclinical
selumetinib
Sensitive
:
D
NRAS Q61K
Melanoma
NRAS Q61K
Melanoma
trametinib
Resistant: D – Preclinical
trametinib
Resistant
:
D
trametinib
Resistant: D – Preclinical
trametinib
Resistant
:
D
NRAS Q61K
Melanoma
NRAS Q61K
Melanoma
SBI-756
Sensitive: D – Preclinical
SBI-756
Sensitive
:
D
SBI-756
Sensitive: D – Preclinical
SBI-756
Sensitive
:
D
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.